Eric Laille

1.6k citations

38 papers · 1.1k indexed · h-index 16

Impact in

Hematology top 1%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
Genetics top 5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in ⓘ

Hematology 27
- Acute Myeloid Leukemia Research 27
- Hematopoietic Stem Cell Transplantation 8
Infectious Diseases 10
- HIV/AIDS drug development and treatment 10

Co-authors: Barry Skikne (15 shared papers)Guillermo Garcia‐Manero (10 shared papers)Steven D. Gore (8 shared papers)Kyle J. MacBeth (8 shared papers)Christopher R. Cogle (8 shared papers)Hagop M. Kantarjian (4 shared papers)Tao Shi (4 shared papers)Joel Hetzer (5 shared papers)
Journals: Blood (12 papers)Journal of Clinical Oncology (5 papers)Cancer Chemotherapy and Pharmacology (2 papers)Biology of Blood and Marrow Transplantation (2 papers)The Journal of Clinical Pharmacology (2 papers)
Partner nations: United States Switzerland United Kingdom

In The Last Decade

Eric Laille

37 papers receiving 1.1k citations

Peers

Countries citing papers authored by Eric Laille

Since Specialization

Citations

This map shows the geographic impact of Eric Laille's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Laille with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Laille more than expected).

Fields of papers citing papers by Eric Laille

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric Laille. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Laille. The network helps show where Eric Laille may publish in the future.

Co-authors

The 25 scholars most cited alongside Eric Laille, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Eric Laille Line = papers co-authored together Eric Laille links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Blood ·Guillermo Garcia‐Manero, Sarit Assouline, Jörge E. Cortes, Zeev Estrov, Hagop M. Kantarjian, Hui Yang, Willie Newsome, Wilson H. Miller, Caroline Rousseau, Ann Kalita, Claire Bonfils, Marja Dubay, T. Patterson, Zuomei Li, Jeffrey M. Besterman, Gregory K. Reid, Eric Laille, Robert E. Martell, Mark D. Minden	2008	194
2	Phase I Study of Oral Azacitidine in Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, and Acute Myeloid Leukemia Journal of Clinical Oncology ·Guillermo Garcia‐Manero, Steven D. Gore, Christopher R. Cogle, Renee Ward, Tao Shi, Kyle J. MacBeth, Eric Laille, Heidi Giordano, Sarah Sakoian, Elias Jabbour, Hagop M. Kantarjian, Barry Skikne	2011	193
3	CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes Biology of Blood and Marrow Transplantation ·Marcos de Lima, Betül Oran, Richard E. Champlin, Esperanza B. Papadopoulos, Sergio Giralt, Bart L. Scott, Basem M. William, Joel Hetzer, Eric Laille, Becky Hubbell, Barry Skikne, Charles Craddock	2018	115
4	Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors Journal of Clinical Oncology ·Lillian L. Siu, Роберто Пили, Ignacio Durán, Wells A. Messersmith, Eric X. Chen, Rana Sullivan, Martha MacLean, Serina King, Shirley Brown, Gregory K. Reid, Zuomei Li, Ann Kalita, Eric Laille, Jeffrey M. Besterman, Robert E. Martell, Michael A. Carducci	2008	104
5	Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes Leukemia ·Guillermo Garcia‐Manero, Steven D. Gore, Suman Kambhampati, Bart L. Scott, Ayalew Tefferi, Christopher R. Cogle, William J. Edenfield, Joel Hetzer, Kailash Kumar, Eric Laille, Tao Shi, Kyle J. MacBeth, B. Skikne	2015	86
6	Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies PLoS ONE ·Eric Laille, Tao Shi, Guillermo Garcia‐Manero, Christopher R. Cogle, Steven D. Gore, Joel Hetzer, Keshava Kumar, Barry Skikne, Kyle J. MacBeth	2015	48
7	Extended dosing with CC‐486 (oral azacitidine) in patients with myeloid malignancies American Journal of Hematology ·Michael R. Savona, Kathryn S. Kolibaba, Paul Conkling, Edwin Kingsley, Carlos Becerra, John C. Morris, Robert M. Rifkin, Eric Laille, A. J. Kellerman, Stacey M. Ukrainskyj, Qian Dong, Barry Skikne	2018	45
8	Treatment of relapsed or refractory non-hodgkin lymphoma with the oral isotype-selective histone deacetylase inhibitor MGCD0103: Interim results from a phase II study Journal of Clinical Oncology ·Michael Crump, C. Andreadis, Sarit Assouline, David A. Rizzieri, Amanda Wedgwood, P. McLaughlin, Eric Laille, Z. Li, Robert E. Martell, Anas Younes	2008	30
9	Phase I Study of CC-486 Alone and in Combination with Carboplatin or nab-Paclitaxel in Patients with Relapsed or Refractory Solid Tumors Clinical Cancer Research ·Daniel D. Von Hoff, Drew Rasco, Elisabeth I. Heath, Pamela N. Münster, Jan H.M. Schellens, Nicolás Isambert, Christophe Le Tourneau, Bert H. O’Neil, Ron H.J. Mathijssen, José A. López-Martín, W. Jeff Edenfield, Miguel Martín, Patricia LoRusso, Gordon L. Bray, Jorge DiMartino, Aaron Nguyen, Kejian Liu, Eric Laille, Johanna C. Bendell	2018	27
10	Pharmacokinetics of different formulations of oral azacitidine (CC‐486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies The Journal of Clinical Pharmacology ·Eric Laille, Michael R. Savona, Bart L. Scott, Thomas E. Boyd, Qian Dong, Barry Skikne	2013	26
11	Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML). Blood ·Guillermo Garcia‐Manero, Allen S. Yang, Virginia M. Klimek, Jörge E. Cortes, Farhad Ravandi, Willie Newsome, Julie Dumouchel, Marja Dubay, Zoumei Li, Christiane R. Maroun, Eric Laille, Hagop M. Kantarjian, Robert E. Martell, Selina M. Luger	2007	25
12	Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study International Journal of Hematology ·Dai Maruyama, Kensei Tobinai, Michinori Ogura, Toshiki Uchida, Kiyohiko Hatake, Masafumi Taniwaki, Kiyoshi Ando, Kunihiro Tsukasaki, Takashi Ishida, Naoki Kobayashi, Kenichi Ishizawa, Yoichi Tatsumi, Koji Kato, Toru Kiguchi, Takayuki Ikezoe, Eric Laille, Tokihiro Ro, Hiromi Tamakoshi, Sanae Sakurai, Tomoko Ohtsu	2017	24
13	A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy ·Eric Laille, Sanjay Goel, Alain C. Mita, Nashat Gabrail, Kevin R. Kelly, Liangang Liu, Stephen Songer, Charles L. Beach	2013	16
14	Plasma concentrations of praziquantel after oral administration of single and multiple doses in loggerhead sea turtles ( Caretta caretta ) American Journal of Veterinary Research ·Elliott R. Jacobson, Glenn R. Harman, Lara K. Maxwell, Eric Laille	2003	16
15	Phase I/II: The oral isotype-selective HDAC inhibitor MGCD0103 in combination with gemcitabine (Gem) in patients (pts) with refractory solid tumors Journal of Clinical Oncology ·H. Hurwitz, Barbara Scott Nelson, P J O'Dwyer, E. Gabriela Chiorean, N. Gabrail, Z. Li, Eric Laille, M. Drouin, Mace L. Rothenberg, Eric Chun Yong Chan	2008	16
16	Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with high-resolution mass spectrometry Journal of Pharmaceutical and Biomedical Analysis ·Ellen J. B. Derissen, M. J. X. Hillebrand, Hilde Rosing, Hans Martin Otten, Eric Laille, Jan H.M. Schellens, Jos H. Beijnen	2013	15
17	Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T Cell Product Manufactured By Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) Blood ·Nitin Jain, Patrice Chevallier, Hongtao Liu, Gary J. Schiller, Jean-Baptiste Méar, Daniel J. DeAngelo, Kevin J. Curran, Stephan A. Grupp, André Baruchel, Marie Balsat, Alexandra LaCroce, Caroline Roudet, Ana Korngold, Kathryn J. Newhall, Eric Laille, Daniel J. Lee, Mark G. Frattini, Richard A. Larson, Nicolas Boissel	2023	13
18	A phase Ia study of CC-90003, a selective extracellular signal-regulated kinase (ERK) inhibitor, in patients with relapsed or refractory BRAF or RAS-mutant tumors. Journal of Clinical Oncology ·Monica Mita, Patricia LoRusso, Grant A. McArthur, Edward S. Kim, Gordon L. Bray, Nanette Hock, Eric Laille, Ida Aronchik, Ellen Filvaroff, Xiaoling Wu, Johanna C. Bendell	2017	11
19	In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine Cancer Chemotherapy and Pharmacology ·Yong Chen, Lisa Liu, Eric Laille, Gondi Kumar, Sekhar Surapaneni	2010	9
20	Efficacy, safety and pharmacokinetics of subcutaneous azacitidine in Chinese patients with higher risk myelodysplastic syndromes: Results from a multicenter, single‐arm, open‐label phase 2 study Asia-Pacific Journal of Clinical Oncology ·Xin Du, Yue‐Yun Lai, Zhijian Xiao, Ting Liu, Yu Hu, Aining Sun, Xiao Li, Zhixiang Shen, Jie Jin, Li Yu, Eric Laille, Qian Dong, Stephen Songer, C.L. Beach	2017	9

About Eric Laille

Eric Laille is a scholar working on Hematology, Infectious Diseases, Genetics, Oncology and Genetics, having authored 38 papers that have together received 1.1k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (27 papers), Histone Deacetylase Inhibitors Research (13 papers), HIV/AIDS drug development and treatment (10 papers), Hematopoietic Stem Cell Transplantation (8 papers), Pneumocystis jirovecii pneumonia detection and treatment (6 papers), Blood disorders and treatments (6 papers), Epigenetics and DNA Methylation (5 papers) and Hemoglobinopathies and Related Disorders (4 papers). The work is most often cited by research in Hematology (631 citations), Genetics (165 citations), Molecular Biology (703 citations), Oncology (208 citations) and Public Health, Environmental and Occupational Health (104 citations). Eric Laille has collaborated with scholars based in United States, Switzerland and United Kingdom. Frequent co-authors include Barry Skikne, Guillermo Garcia‐Manero, Steven D. Gore, Kyle J. MacBeth, Christopher R. Cogle, Hagop M. Kantarjian, Tao Shi, Joel Hetzer, Robert E. Martell and Bart L. Scott. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Biology of Blood and Marrow Transplantation and The Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact